Radiotherapy devices market seen reaching $10.18B by 2030

The radiotherapy devices market is projected to grow from $6.64 billion in 2025 to $7.21 billion in 2026, with long-term forecasts pointing to $10.18 billion by 2030. Rising cancer cases, faster adoption of advanced radiation systems and more investment in AI and proton therapy are driving the outlook.

Why it matters: - Radiotherapy devices are a core part of cancer care because they target tumors while limiting damage to healthy tissue. - Faster market growth signals more spending on oncology infrastructure, treatment planning tools and radiation delivery systems. - Rising demand could improve access to treatments such as external beam radiation, brachytherapy and proton therapy.

What happened: - The Business Research Company published a 2026 market report on radiotherapy devices covering the market outlook from 2026 to 2035. - The market is projected to rise from $6.64 billion in 2025 to $7.21 billion in 2026, implying 8.6% growth. - The market is expected to reach $10.18 billion by 2030, at a forecast CAGR of 9.0%. - North America held the largest share of the global market in 2025. - Asia-Pacific ranked second by market size in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also offered a free sample report and the full market report online: Download a free sample and View the full report.

The details: - Market growth is being driven by higher cancer incidence worldwide. - The market is also benefiting from the expansion of oncology treatment facilities. - Wider use of external beam radiation therapies is supporting demand. - Improvements in linear accelerator technology are strengthening device capability. - Greater access to advanced radiotherapy methods is widening adoption. - Future growth is tied to demand for personalized cancer therapies. - Investment in proton therapy centers is expected to add momentum. - AI-assisted oncology workflows are becoming more important in treatment planning. - Radiation side-effect reduction is a major focus for product development. - Innovation in radiation delivery systems remains a key market driver. - The report highlights growing use of image-guided radiation therapy. - The report also points to broader adoption of proton therapy, AI-enabled treatment planning, stereotactic radiation techniques and more precise dose delivery. - In July 2024, Australian Institute of Health and Welfare data showed cancer diagnoses in Australia rising from 160,570 in 2022 to 164,694 in 2023.

Between the lines: - The report points to a market shifting from basic radiation delivery toward more precise, software-enabled and image-guided care. - North America’s lead suggests the region has the deepest installed base and spending power, while Asia-Pacific remains the main growth challenger. - The emphasis on AI and proton therapy suggests providers are prioritizing precision and lower toxicity, not just volume.

What's next: - The market is likely to keep expanding as cancer incidence rises and healthcare systems upgrade oncology capacity. - Adoption of AI-enabled planning and image-guided techniques should shape the next wave of product demand. - Proton therapy and stereotactic radiation are likely to gain more attention as providers look for more targeted treatment options. - The Business Research Company said its 2026 report also adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, technology analysis and updated graphics and tables.